Followers | 325 |
Posts | 20140 |
Boards Moderated | 5 |
Alias Born | 12/15/2012 |
Sunday, February 05, 2017 3:33:08 PM
http://www.plandaibiotech.com/president.html
Quote:
We will, of course, continue our pharmaceutical testing. We have additional malaria trials set to commence next year using a combination green tea and artemisia drug, and we will be conducting a sports recover and sports injury trial using our citrus product. Once the cannabis product is profiled, our intent is to start testing for treating neural disorders including MS, Parkinson’s and epilepsy.
NanoViricides Reports that the Phase I NV-387 Clinical Trial is Completed Successfully and Data Lock is Expected Soon • NNVC • May 2, 2024 10:07 AM
ILUS Files Form 10-K and Provides Shareholder Update • ILUS • May 2, 2024 8:52 AM
Avant Technologies Names New CEO Following Acquisition of Healthcare Technology and Data Integration Firm • AVAI • May 2, 2024 8:00 AM
Bantec Engaged in a Letter of Intent to Acquire a Small New Jersey Based Manufacturing Company • BANT • May 1, 2024 10:00 AM
Cannabix Technologies to Deliver Breath Logix Alcohol Screening Device to Australia • BLO • Apr 30, 2024 8:53 AM
Hydromer, Inc. Reports Preliminary Unaudited Financial Results for First Quarter 2024 • HYDI • Apr 29, 2024 9:10 AM